First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Razak, Albiruni R. A.
Soerensen, Morten Mau
Mahipal, Amit
Shacham, Sharon
Yau, Cindy Y. F.
Lassen, Ulrik Niels
McCauley, Dilara
Cooksey, Jennifer
Tan, David Shao Peng
Saint-Martin, Jean-Richard
Landesman, Yossi
Pond, Gregory
Oza, Amit M.
Kauffman, Michael
Siu, Lillian L.
Mirza, Mansoor Raza
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Karyopharm Therapeut, Newton, MA USA
[5] Ozmosis Res Inc, Toronto, ON, Canada
[6] Rigshosp, DK-2100 Copenhagen, Denmark
[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Coyle, Victoria
    Evans, T. R. Jeffry
    Plummer, Elizabeth Ruth
    Clive, Sally
    McGuigan, Lesley
    Roxburgh, Patricia
    Haris, Noor Md
    Symeonides, Stefan N.
    Naylor, Gregory
    Bashir, Saira
    Stanley, Barbara
    Godfrey, Lisa
    Elliott, Moira
    Halbert, Gavin
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
    Forster, M. D.
    Patnaik, A.
    Sandhu, S. K.
    Papadopoulos, K.
    Tromp, B. J.
    Messiou, C.
    Balkwill, F.
    Berns, B.
    De Bono, J. S.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [34] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elena Elez
    Carlos Gomez-Roca
    Arturo Soto Matos-Pita
    Guillem Argiles
    Thibaud Valentin
    Cinthya Coronado
    Jorge Iglesias
    Teresa Macarulla
    Sarah Betrian
    Salvador Fudio
    Katrin Zaragoza
    Josep Tabernero
    Jean-Pierre Delord
    Investigational New Drugs, 2019, 37 : 674 - 683
  • [35] A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.
    Gabrail, Nashat Y.
    Hamilton, Erika P.
    Elias, Anthony D.
    Rimawi, Mothaffar F.
    Li, Chao
    Corvez, Maria Margarita
    Li, Wei
    Feng, Ying
    Wei, Jiao
    Greene, Stephanie
    Patterson, John
    Zeng, Qingping
    Hui, Ai-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.
    Meric-Bernstam, Funda
    Sharma, Manish
    Sommerhalder, David
    Skeel, Roland T.
    El-Khoueiry, Anthony B.
    Caswell-Jin, Jennifer Lee
    Patel, Premal H.
    Rosen, Ezra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.
    Yap, Timothy A.
    Tolcher, Anthony W.
    Plummer, Elizabeth Ruth
    Becker, Andreas
    Fleuranceau-Morel, Patricia
    Goddemeier, Thomas
    Locatelli, Giuseppe
    Gounaris, Ioannis
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] KCP-330-005/SIGN: A PHASE II, OPEN-LABEL STUDY OF EFFICACY AND SAFETY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) KPT-330 (SELINEXOR) IN PATIENTS WITH ADVANCED GYNAECOLOGIC MALIGNANCIES
    Vergote, I.
    Lund, B.
    Ujmajuridze, Z.
    Havsteen, H.
    Rashal, T.
    Marshall, T.
    McCartney, J.
    Kauffman, M.
    Shacham, S.
    Mirza, M. R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1182 - 1183
  • [39] First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma
    Yap, T.
    Desai, J.
    Dagogo-Jack, I.
    Millward, M.
    Kindler, H. L.
    Tolcher, A. W.
    Frentzas, S.
    Body, A. L.
    Thurston, A.
    Post, L.
    Dorr, F. A.
    Kwiatkowski, D. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S384 - S384
  • [40] A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
    Hong, David S.
    Kurzrock, Razelle
    Supko, Jeffrey G.
    He, Xiaoying
    Naing, Aung
    Wheler, Jennifer
    Lawrence, Donald
    Eder, Joseph Paul
    Meyer, Colin J.
    Ferguson, Deborah A.
    Mier, James
    Konopleva, Marina
    Konoplev, Sergej
    Andreeff, Michael
    Kufe, Donald
    Lazarus, Hillard
    Shapiro, Geoffrey I.
    Dezube, Bruce J.
    CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3396 - 3406
12345